본문으로 건너뛰기
← 뒤로

Antibody-drug conjugates in oncology: A spotlight on overcoming resistance.

1/5 보강
Critical reviews in oncology/hematology 📖 저널 OA 10.6% 2022: 0/3 OA 2023: 0/2 OA 2024: 0/4 OA 2025: 0/56 OA 2026: 32/236 OA 2022~2026 2026 Vol.217() p. 105015
Retraction 확인
출처

Xu X, Yu T, Wang Z

📝 환자 설명용 한 줄

Antibody-drug conjugates (ADCs), which combine precise monoclonal antibodies with cytotoxic payloads, represent a transformative class of anticancer therapeutics.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Xu X, Yu T, Wang Z (2026). Antibody-drug conjugates in oncology: A spotlight on overcoming resistance.. Critical reviews in oncology/hematology, 217, 105015. https://doi.org/10.1016/j.critrevonc.2025.105015
MLA Xu X, et al.. "Antibody-drug conjugates in oncology: A spotlight on overcoming resistance.." Critical reviews in oncology/hematology, vol. 217, 2026, pp. 105015.
PMID 41223981 ↗

Abstract

Antibody-drug conjugates (ADCs), which combine precise monoclonal antibodies with cytotoxic payloads, represent a transformative class of anticancer therapeutics. Despite their clinical success, resistance mechanisms significantly limit their therapeutic utility. This review systematically summarizes the multifaceted mechanisms underlying ADC resistance, including antibody-related factors, aberrant intracellular trafficking, payload-related factors, and dysregulated survival signaling. We further evaluated strategies to overcome resistance, including third-generation ADCs, novel payloads, and multimodal combination therapies. By integrating preclinical insights and clinical advancements, this review provides a theoretical framework for optimizing ADC efficacy and overcoming therapeutic resistance in oncology.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반